- Messages
- 1
- Best answers
- 0
Can anyone help me with the billing guidelines for Apligraf HCPCS Q4101? Nedd some info for a job interview.
-
If this is your first visit, be sure to check out the FAQ & read the forum rules. To view all forums, post or create a new thread, you must be an AAPC Member. If you are a member and have already registered for member area and forum access, you can log in by clicking here. If you've forgotten your username or password use our password reminder tool. To start viewing messages, select the forum that you want to visit from the selection below..
Wiki Biologics
- Thread starter ALISAHOLLIDAY2@NETZERO.COM
- Start date
MJ4ever
Guru
This link may have what you are looking for:
http://www.trailblazerhealth.com/Tools/LCDs.aspx?DomainID=1
The following indications and limitations to Medicare coverage and payment apply to the specified bioengineered skin substitutes and their related skin substitute application physician services.
Apligraf® (Q4101) Indications:
Neuropathic diabetic foot ulcer.
Venous stasis ulcer.
Apligraf® (Q4101) Limitations:
Medicare payment for Apligraf® is limited to five applications per ulcer, though more than three applications of Apligraf® to a single wound are usually unnecessary.
Medicare does not cover continued reapplication of Apligraf® when the treatment is unsuccessful after 30 days of treatment.
Medicare does not cover retreatment of an ulcer following an unsuccessful course of treatment.
Medicare does not cover retreatment of a successfully treated, healed ulcer.
See “Coding Guidelines” regarding required use of the KX modifier with Q4101, Q4102, Q4106, Q4107 and 15330–15431 and G0440-G0441 to report skin substitute products that have been handled, applied and immobilized appropriately and according to manufacturers’ label instructions.
http://www.trailblazerhealth.com/Tools/LCDs.aspx?DomainID=1
The following indications and limitations to Medicare coverage and payment apply to the specified bioengineered skin substitutes and their related skin substitute application physician services.
Apligraf® (Q4101) Indications:
Neuropathic diabetic foot ulcer.
Venous stasis ulcer.
Apligraf® (Q4101) Limitations:
Medicare payment for Apligraf® is limited to five applications per ulcer, though more than three applications of Apligraf® to a single wound are usually unnecessary.
Medicare does not cover continued reapplication of Apligraf® when the treatment is unsuccessful after 30 days of treatment.
Medicare does not cover retreatment of an ulcer following an unsuccessful course of treatment.
Medicare does not cover retreatment of a successfully treated, healed ulcer.
See “Coding Guidelines” regarding required use of the KX modifier with Q4101, Q4102, Q4106, Q4107 and 15330–15431 and G0440-G0441 to report skin substitute products that have been handled, applied and immobilized appropriately and according to manufacturers’ label instructions.
Last edited: